The Molecular Biology and Treatment of Malignant Melanoma with BRAFV600 Mutations
Since 2011, the treatment options for metastatic malignant melanoma have significantly changed. In that year, ipilimumab, an anti-CTLA4 monoclonal antibody, and vemurafenib, a potent inhibitor of mutated-BRAF (V600E and V600K), were approved by the U.S. Food and Drug Administration (FDA). In 2013, d...
Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Advocate Aurora Health
2014-01-01
|
| coleção: | Journal of Patient-Centered Research and Reviews |
| Assuntos: | |
| Acesso em linha: | http://digitalrepository.aurorahealthcare.org/cgi/viewcontent.cgi?article=1007&context=jpcrr |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|